Cannabis Science Inc (OTCMKTS:CBIS) is delighted to announce that the delivery of the first of the per-designed greenhouses that have full tracking and reporting protocols.
The company specializes in development of cannabis related medicine is excited with the news which will be delivered from their Nevada and California operations. CBIS has received numerous inquiries in its mailbox about the timing of the clinical research as well as the availability of the treatment varieties. The inquiries range from peripheral neuropathies, management of pain, COPD and cancer. The inquiries are received in the in-house database and the company will be responding to each one of then as each target observational research begins. The studies will involve a variety of more than 500 cannabinoids that have been set apart and marked from Cannabis sativa.
Sentiments of the company
The company feels that having control over their supply chain will play a huge part in enhancing their efficiency. This includes the cost and the time necessary to have the products ready for any development into all the formulations. The company hopes to soon unveil their studies for particular cannabinoid combinations of the formulations and testing. The formulations are uniquely made to target particular critical ailments, to work in a certain unique delivery mode as well as to have the ability to send maximum positive results in a patients consumption.
Types of phytocannabinoids
Some of the common cannabinoid plants (phytocannabinoids) include tetrahydrocannabinol (THC), cannabichromene (CBC), cannabigerol (CBG), cannabidiol (CBD) and cannabinol (CBN). THC is the main psychoative content of cannabis and its pharmacology has been studied in great depth. The company is in the progress of developing the foundation of patient centered outcomes research (PCOR) for a range of critical conditions.
CBIS will then come up with the protocols for the international consortium including U.S., European and South African universities and research centers. The consortium will concurrently design protocols for clinical trials and animal studies for certain critical ailments. The studies will mainly focus on PTSD, HIV/AIDS, cancers, pain management and neurological conditions. All the countries will make sure to follow the set guidelines for approval by U.S. Food and Drug Administration as well as the approvals in that country.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide innovative treatment options for unmet medical needs.
Cannabis use has an extensive history dating back thousands of years, and currently there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.
At Cannabis Science, we use an inquiring approach to discover and develop novel cannabinoid-based therapies to improve patients’ lives. From the initiation, our founders have been committed to fostering and maintaining a bold, pioneering spirit fostering the true nature of innovation from which cutting edge ideas flourish and translate into evidence-based solutions.
We are dedicated to working closely with local, national and international regulatory agencies to provide access to high quality, first class cannabinoid pharmaceuticals to those critically in need of new treatments for life threatening and debilitating conditions. Cannabis Science’s clinical trial material comes from the cultivation and production facilities that are cGMP compliant, surpassing high quality standard industrial and food processing requirements.
The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of multiple critical ailments from cancer and infections to age-related illnesses and neurobehavioral disorders.
Our products, broadly described, are medical cannabinoid formulations developed from one or more of the cannabinoid compounds found in the cannabis plant. Our immediate focus is to treat one of the most important diseases in the world, cancer.
In 2013, Cannabis Science submitted patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders" (CS-NEURO-1). The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders.
Cannabis plants have extensive history of medical and agricultural use dating back thousands of years.
To date hundreds of natural constituents covering several chemical classes have been isolated and identified from the Cannabis plant.
Some key phytocannabinoids are:
- tetrahydrocannabinol (THC)
- cannabidiol (CBD)
- cannabigerol (CBG)
- cannabichromene (CBC)
- cannabinol (CBN)
These cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the most psychoactive cannabinoid, THC. Some applications of cannabinoids have been well established in peer-reviewed literature such as for alleviating nausea and stimulating the appetite for people with AIDS and cancer. Other well-known uses include easing chronic pain and reducing muscle spasms associated with multiple sclerosis and spinal cord injuries.
The pharmacology of THC has been widely studied, while many other identified cannabinoids are still poorly characterized pharmacologically and biologically, with new activities for cannabinoids consistently being discovered.
Cannabis Science is developing novel cannabis based approaches to treat the world’s most deadly illnesses. We learn from patients about the healing properties of cannabis medicines. Our immediate focus is the development of cutting edge cancer treatments.
The Company’s future endeavors include infectious illnesses, neurobehavioral disorders including attention deficit disorder, post-traumatic stress disorder; and an application of the anti-inflammatory activities of cannabis in the management of age-related illnesses.
The endocannabinoid system possessed by all vertebrates regulates all body systems and maintains homeostasis. As such, the mechanisms of phytocannabinoids’ biological impact are multidimensional.
While concentrating on our core activities of discovering and developing treatments that will make a meaningful difference in patients’ lives, we remain mindful that we have other responsibilities to the clinicians who utilize our drugs, health authorities around the world, our shareholders, our employees, and the communities in which we live and work. We continually strive to improve our corporate responsibility standards and activities, implementing comprehensive ethical standards and undertaking patient and community progressive initiatives.
These principles reflect the mission of Cannabis Science to provide innovative therapeutics for unmet medical needs.
As the industry leader, Cannabis Science consults and leads other emerging businesses that Cannabis Science believes has a preferred business model, one which will mature into a key business model in the future. Our consulting is on the entire "seed to sale" process with a focus on bio-pharmaceutical development.
Cannabis Science is one of the longest standing companies in the cannabis business.
We feel that the correct way is to look at the industry from a bio-pharmaceutical standpoint, in a manner that allows cannabinoid-based products to modulate the endocannabinoid system to treat multiple conditions. Scientifically, we know this is the beginning of one of the greatest expansions of medicine and industry we will ever experience in our lifetime.
Cannabis Science, Inc. is a patient oriented company dedicated to meeting the needs of the community with products based on cannabinoid science, as well as being an advocate for patient rights throughout the world.